#13: Data Demonstrate ORENCIA(R) (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Quality in Children With Juvenile Idiopathic Arthritis
Bristol-Myers
Squibb Company (NYSE: BMY) today announced at the American College
of Rheumatology (ACR) Annual Scientific Meeting in San Francisco results
from a...
AUSTIN, Texas--(BUSINESS WIRE)--United Devices (UD) said today that Bristol-Myers Squibb Company (NYSE:BMY) has engaged UD to build a high performance computing (HPC) grid to manage the...
PRINCETON, N.J. & WALTHAM, Mass.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Adnexus™ Therapeutics today announced a worldwide strategic alliance to discover,...
PRINCETON, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Gilead Sciences, Inc.
(Nasdaq:GILD) today announced an agreement to commercialize...
PRINCETON, New Jersey et FOSTER CITY, Californie--(BUSINESS WIRE)--15 juillet 2006-- L’administration américaine des denrées et des médicaments (FDA) approuve l'ATRIPLA(TM) (éfavirenz...
#7: BMY News US-Arzneimittelzulassungsbehörde FDA genehmigt ATRIPLA(TM) (Efavirenz 600 mg/ Emtricitabin 200 mg/ Tenofovir Disoproxil Fumarat 300 mg), die erste Therapie in Form einer einzigen einmal täglich einzunehmenden Tablette für Erwachsene mit...
PRINCETON, US-Bundesstaat New Jersey, und FOSTER CITY, US-Bundesstaat Kalifornien--(BUSINESS WIRE)--14. Juli 2006-- US-Arzneimittelzulassungsbehörde FDA genehmigt ATRIPLA(TM) (Efavirenz 600...
#6: BMY News Riassunto: L’ente statunitense preposto al controllo dei farmaci e degli alimenti (Food and Drug Administration, FDA) approva ATRIPLA(TM) (efavirenz 600 mg/ emtricitabina 200 mg/ tenofovir disoproxil fumarato 300 mg)
PRINCETON, New Jersey, e FOSTER CITY, California--(BUSINESS WIRE)--12 luglio 2006-- Il primo regime di pastiglie monodose a somministrazione quotidiana per adulti con infezione da HIV-1...
#3: BMY News Resumen: La Agencia de Alimentos y Fármacos de EE.UU. (FDA) aprueba ATRIPLA(TM) (efavirenz 600 mg/ emtricitabina 200 mg/ fumarato de tenofovir 300 mg), el primer tratamiento de una sola dosis diaria para adultos infectados por HIV-1
PRINCETON, Nueva Jersey y FOSTER CITY, California--(BUSINESS WIRE)--12 julio, 2006-- BIOWIRE2K Bristol-Myers Squibb Company (NYSE:BMY) y Gilead Sciences, Inc. (Nasdaq:GILD) han comunicado que han...
#4: BMY News Samenvatting: Amerikaanse Food and Drug Administration keurt Atripla, de eerste één-dagelijkse tablet voor volwassenen met HIV-1 infectie, goed
PRINCETON, New Jersey en FOSTER CITY, Californië--(BUSINESS WIRE)--12 juli, 2006-- Bristol-Myers Squibb Company (NYSE:BMY) en Gilead Sciences (Nasdaq:GILD) melden dat de Amerikaanse Food and Drug...
#5: BMY News U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection
PRINCETON, N.J. and FOSTER CITY, Calif.--(BUSINESS WIRE)--July 12, 2006-- Product Developed Through U.S. Joint Venture between Bristol-Myers Squibb and Gilead Sciences, the First of Its Kind...
#2: BMY News FDA Accepts ERBITUX(R) (Cetuximab) sBLA Submission for the Treatment of Squamous Cell Carcinoma of the Head and Neck and Grants Priority Review
NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--Oct. 31, 2005--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug...
--(BUSINESS WIRE)--According to a national survey of people living with HIV/AIDS, commitment and a strong physician-patient dialogue plays a large role in how patients keep up with their medication...
